Douglas Hughes Biography and Net Worth

Director of Immunovant

Doug Hughes has served as a member of our board of directors since September 2020. Since 2019, Mr. Hughes has served as Chief Financial Officer of Calyxo Inc., a urology medical device company. From 2011 until 2018, Mr. Hughes was Chief Financial Officer of NeoTract, Inc., a urology company. He served as Chief Financial Officer and Chief Operating Officer for Nellix, Inc., an endovascular graft company from 2010 until 2011. Before joining Nellix, Inc., Mr. Hughes served as Chief Financial officer for Evalve Inc., a cardiovascular company, from 2009 until 2010. Prior to 2009, Mr. Hughes held a variety of senior finance management positions at Boston Scientific, Guidant Corporation and The Clorox Company. Mr. Hughes is currently a member of the board of directors of Immunovant, Inc., a publicly-held biopharmaceutical company. Mr. Hughes received a B.S. in Finance from San Francisco State University and an M.B.A. from University of Chicago.

What is Douglas J. Hughes' net worth?: The estimated net worth of Douglas J. Hughes is at least $2.77 million as of December 1st, 2025. Mr. Hughes owns 120,773 shares of Immunovant stock worth more than $2,766,909 as of December 4th. This net worth approximation does not reflect any other investments that Mr. Hughes may own. Learn More about Douglas J. Hughes' net worth.
How do I contact Douglas J. Hughes?: The corporate mailing address for Mr. Hughes and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Douglas J. Hughes' contact information.
Has Douglas J. Hughes been buying or selling shares of Immunovant?: During the last quarter, Douglas J. Hughes has sold $348,600.00 in shares of Immunovant stock. Most recently, Douglas J. Hughes sold 15,000 shares of the business's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $23.24, for a transaction totalling $348,600.00. Following the completion of the sale, the director now directly owns 120,773 shares of the company's stock, valued at $2,806,764.52. Learn More on Douglas J. Hughes' trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Andrew Fromkin (Director), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 16,845,010 shares worth more than $336,900,200.00. During the last twelve months, insiders at the sold shares 24 times. They sold a total of 144,908 shares worth more than $2,858,711.88. The most recent insider tranaction occured on December, 1st when Director Andrew J Fromkin sold 22,249 shares worth more than $517,289.25. Insiders at Immunovant own 1.8% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 12/1/2025.

Douglas J. Hughes Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/1/2025	Sell	15,000	$23.24	$348,600.00	120,773
8/27/2021	Buy	18,247	$8.24	$150,355.28

Douglas J. Hughes Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $22.91

$22.29

$23.31

50 Day Range

MA: $20.79

$16.06

$24.82

2 Week Range

Now: $22.91

$12.72

$29.49

Volume

1,318,878 shs

Average Volume

1,268,560 shs

Market Capitalization

$4.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56